Tagged with ARM

China Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up to 2025 with annual growth of 9.4 percent. Read on for five key trends to watch out for in the…

China The top 10 Chinese pharma companies for 2022, ranked by sales value and based on data from the latest Forbes Global 2000 ranking. Big conglomerates like Sinopharm, Shanghai Pharmaceuticals, and Jointown dominate the list, while other national champions in the midst of expanding their innovation efforts like Jiangsu Hengrui and…

Italy Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added medicines sector, and biotech. Massimo Scaccabarozzi, former President of Farmindustria; Michele Uda, director general of Egualia, and Leonardo Vingiani, managing…

China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics.   Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…

Singapore Japanese giant Takeda has a new Head for APAC; Indian national Dr Mahender Nayak, previously the firm’s India, CIS, Middle East, Turkey & Africa (ICMEA) lead. Nayak will relocate to Singapore, where he has spent almost half of his 20-year pharma career, and take on responsibility for the vast Asia-Pacific…

India As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality compliance issues. After Sun Pharma, Aurobindo and Zydus found themselves on the FDA’s radar earlier this year, two more Indian…

Mexico Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers, some industry insiders are bemoaning the current government’s healthcare missteps along with the country’s low public spending and regulatory hurdles.…

Hong Kong After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange went from 20 new listings last year to only four this year, with just three full months of 2022 remaining…

Mexico The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and revenue increases are being seen despite regulatory backlog and medicine shortages due to inefficient handling of the public system. He…

Pharma Legal Handbook Regulatory, pricing and reimbursement overview in Italy – a legal guide. Prepared in association with Baker Mckenzie, a leading law firm in Italy, this is an extract from The Pharma Legal Handbook: Italy, available to purchase here for GB 119.   1. What are the regulatory authorities with jurisdiction over…

Pharma Legal Handbook Key legal info on preclinical and clinical trial requirements in Italy. Prepared in association with Baker Mckenzie, a leading law firm in Italy, this is an extract from The Pharma Legal Handbook: Italy, available to purchase here for GB 119.   1. Are clinical trials required to be conducted locally…

Pharma Legal Handbook All about marketing, manufacturing, packaging & labeling, advertising in Italy. Prepared in association with Baker Mckenzie, a leading law firm in Italy, this is an extract from The Pharma Legal Handbook: Italy, available to purchase here for GB 119.   1. What is the authorization process for the marketing of new drugs,…